Risperidone

利培酮

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameRisperidone
Drug Alias NameRisperidona利司哌酮利螺环酮RisperidonumRisperdal Consta (利培酮) +[26] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor antagonists
TargetsSerotonin 2a (5-HT2a) receptorDopamine D2 receptor
Therapy Area/IndicationsBipolar I DisorderStress Disorders, Post-TraumaticAdjustment Disorders +[36] 
Global Approved IndicationsSchizophreniaPsychotic DisordersBipolar Disorder
Approved Indications in ChinaSchizophreniaPsychotic DisordersBipolar Disorder
Original Approved Country/TerritoryUnited States
Original Approved Date1993/12/29
Country/TerritoryBulgariaUnited StatesUkraine +[31] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesLaboratorios Farmacéuticos Rovi SaUniversity Of TehranUniversity Of Rochester +[14] 
Inactive CompaniesJanssen-Ortho Inc., CanadaUniversity Of California San FranciscoEunice Kennedy Shriver National Institute Of Child Health And Human Development +[34] 
Active IndicationsBipolar I DisorderSchizophreniaPsychotic Disorders +[12] 
Inactive IndicationsStress Disorders, Post-TraumaticAdjustment DisordersDevelopmental Disabilities +[24] 

Other Information

ATC CodeN05AX08
Related LinksWikipediaDrugBankKEGG